Hair loss treatments, specifically about the effectiveness of RU58841 compared to Pyrilutamide. Molecular weights and side effects were discussed in terms of efficacy and cost-effectiveness.
User seeks participants for Verteporfin group buy. Verteporfin, FDA approved, may regenerate hair follicles and sweat glands through heavy microneedling.
A 21-year-old male used 1mg of finasteride since March with no results and suspects a scalp fungus due to pimples and burning sensations. He is seeking advice on treating the potential fungus.
A 51-year-old man uses 1mg oral finasteride daily, 5% topical minoxidil twice daily, dermarolling, and Nizoral twice a week for hair regrowth. He shows significant progress after two months and is happy with the improvement.
The conversation is about a person's one-year progress using finasteride and minoxidil for hair loss, with intermittent use of RU58841, showing improved hair quality, density, and thickness without side effects. Users complimented the improved appearance and suggested the longer hair also enhanced their look.
A 26-year-old male experienced significant hair regrowth using a 4-in-1 topical treatment from Hims, which includes minoxidil, finasteride, ketoconazole, and biotin, over four months. The user reported increased body and beard hair, skin changes, and no negative sexual side effects, while others noted the rapid and impressive results as atypical.
Hair transplant success largely depends on individual biology, with many patients needing multiple procedures to achieve satisfactory density. Even top surgeons can't guarantee results, and many people use additional treatments like Minoxidil and Finasteride.
Breezula's potential as a hair loss treatment is debated, with some seeing promise despite delays, while others suggest alternatives like Pyrilutamide. Breezula is compared to topical finasteride, with hopes for a better side effect profile.
The conversation discusses hair thinning potentially linked to gut health issues and suggests biotin as a possible treatment. It also mentions that hair thinning could be due to male pattern baldness (MPB).
Users discussed hair loss treatments, specifically 0.1% latanoprost with melatonin, caffeine, and biotin. Other treatments mentioned include minoxidil, finasteride, RU58841, and microneedling.
The conversation is about someone planning to start finasteride for hair loss and wanting to interpret pre-treatment blood panels to assess the risk of side effects like gynecomastia. They list various tests to measure hormone levels and other health indicators.
A user shared their successful hair regrowth experience using 1.25mg finasteride daily, alternating oral and topical minoxidil, and weekly dermarolling. They reported significant improvement in their hairline and crown coverage over a year, with minimal side effects.
A user shared progress pictures showing successful hair retention using a low-dose topical finasteride (0.008%) combined with minoxidil. Users discussed the effectiveness of the treatment, minimal effective dosing, and avoiding systemic side effects.
A user is planning to get extensive blood tests before starting Finasteride and is seeking advice on which tests are necessary. They are concerned about the cost and potential redundancy of some tests.
PP405 is seen as a potential breakthrough for converting vellus hairs to terminal hairs, with users expressing both hope and skepticism. It is compared to treatments like minoxidil and finasteride, with discussions on side effects and marketing concerns.
A user with stage 1 hair loss is inquiring about the release date of GT20029, hoping to use it instead of Minoxidil and finasteride, as they believe it has better results. They want to know if it will be available in the next couple of years.
A user is considering using RU58841 for female pattern baldness and is also planning to use Minoxidil. They are hesitant to ask their doctor for spironolactone due to its cosmetic nature and are experiencing significant hair loss possibly due to stress and hormonal issues.
The post is about a user starting a hair loss treatment using finasteride, micro needling, and nizoral. The conversation includes supportive replies from other users.
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
A user shared their experience using RU58841, Minoxidil, and Finasteride for hair loss, noting good results but increased acne from RU58841. They plan to replace RU58841 with Finasteride while continuing Minoxidil.
The conversation is about using finasteride and KX826 for hair loss treatment. The original poster is using 0.25 mg of finasteride every other day due to side effects at a higher dose.
People are discussing the effectiveness of Breezula for hair loss maintenance. Some individuals are using Breezula alone, avoiding finasteride, and one plans to use Breezula after a hair transplant.
B-complex vitamins may improve hair appearance but have limited impact on hair loss. Some users also use minoxidil and finasteride for hair loss treatment.
Pyrilutamide/KX-826 is being considered as a potential treatment for female androgenetic alopecia (AGA), but its high cost and limited data on effectiveness are concerns. Kintor markets it for both men and women.
ET-02 (RS 5441) shows promising results for hair growth, performing better in humans than in mice. There is debate over the effectiveness compared to minoxidil, with some users wanting more detailed data.
The conversation discusses using 1mg Dutasteride daily for hair loss and its effects on hair, acne, and body hair. One user mentions that shedding hair can be a positive sign of new hair growth.
Kintor Pharma completed a successful Phase II clinical trial for KX-826, a treatment for androgenetic alopecia. KX-826 is similar to finasteride with minor side effects and is more backed than Cosmerna.
Clascoterone solution is in Phase III trials for male androgenetic alopecia, with results expected in the second half of 2025. Commercialization is anticipated in about 2-3 years, but there are concerns about delays and market expectations.
The conversation discusses the tension theory of baldness, suggesting that over-developed masseter muscles may harm hair follicles. Botox injections to relax these muscles reportedly led to an 18% increase in hair count in men with AGA.